A recent Phase 1 trial of autogene cevumeran, an individualized neoantigen mRNA–lipoplex vaccine, in combination with atezolizumab (anti‐PD‐L1) and mFOLFIRINOX chemotherapy, reported long‐term immune responses in pancreatic cancer patients.[55] Notably, vaccine responders exhibited a prolonged recurrence‐free survival compared to non‐responders, with CD8+ T cell clones persisting at substantial frequencies 3 years post‐vaccination. The gene discussed is CD274; the disease is familial pancreatic carcinoma.